Publications

RSS Feed

No results.

  1. Development and plasticity of meningeal lymphatic vessels. Antila S, Karaman S, Nurmi H, Airavaara M, Voutilainen MH, Mathivet T, Chilov D, Li Z, Koppinen T, Park J-H, Fang S, Aspelund A, Saarma M, Eichmann A, Thomas J-L, Alitalo K. J Exp Med 214: 3645-3667, 2017.
  2. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. Aspelund A, Antila S, Proulx ST, Karlsen TV, Karaman S, Detmar M, Wiig H, Alitalo K. J Exp Med 212: 991-9, 2015.
  3. The Schlemm’s canal is a VEGF-C/VEGFR-3-responsive lymphatic-like vessel. Aspelund A, Tammela T, Antila S Nurmi H, Leppänen VM, Zarkada G, Stanczuk L, Francois M, Mäkinen T, Saharinen P, Immonen I, Alitalo K. J Clin Invest 124: 3975-3986, 2014.
  4. CCBE1 enhances lymphangiogenesis via a disintegrin and metalloprotease with thrombospondin motifs-3-mediated vascular endothelial growth factor-C activation. Jeltsch M, Jha SK, Tvorogov D, Anisimov A, Leppänen V-M, Holopainen T, Kivelä R, Ortega S, Kärpänen T, Alitalo K. Circulation 129: 1962-1971, 2014.
  5. Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation. Leppänen V-M, Tvorogov D, Kisko K, Prota AE, Jeltsch M, Anisimov A, Markovic-Mueller S, Stuttfeld E, Goldie KN, Ballmer-Hofer K, Alitalo K. Proc Natl Acad Sci USA 110: 12960-12965, 2013.
  6. VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signalling. Tammela T, Zarkada G, Nurmi H, Jakobsson L, Heinolainen K, Tvorogov D, Zheng W, Franco CA, Murtomäki A, Aranda E, Miura N, Ylä-Herttuala S, Fruttiger M, Mäkinen T, Eichmann A, Pollard JW, Gerhardt H, Alitalo K. Nature Cell Biol 13: 1202-1213, 2011.
  7. Photodynamic ablation of lymphatic vessels and intralymphatic cancer cells prevents metastasis. Tammela T, Saaristo A, Holopainen T, Ylä-Herttuala S, Andersson LC, Virolainen S, Immonen I, Alitalo K. Sci Transl Med 3: 69ra11, 2011.
  8. Effective Suppression of Vascular Network Formation by Combination of Antibodies Blocking VEGFR Ligand Binding and Receptor Dimerization. Tvorogov D, Anisimov A, Zheng W, Leppänen V-M, Tammela T, Laurinavicius S, Holnthoner W, Heloterä H, Holopainen T, Jeltsch M, Kalkkinen N, Lankinen H, Ojala P, Alitalo K. Cancer Cell 18: 630-40, 2010.
  9. Structural determinants of growth factor binding and specificity by VEGF-Receptor 2. Leppänen VM, Prota A, Jeltsch M, Anisimov A, Kalkkinen N, Strandin T, Lankinen H, Goldman A, Ballmer-Hofer K, Alitalo K. Proc Natl Acad Sci USA, 107: 2425-2430, 2010.
  10. Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype. Petrova TV, Nykanen A, Norrmen C, Ivanov KI, Andersson LC, Haglund C, Puolakkainen P, Wempe F, von Melchner H, Gradwohl G, Vanharanta S, Aaltonen LA, Saharinen J, Gentile M, Clarke A, Taipale J, Oliver G, Alitalo K. Cancer Cell 13: 407-19, 2008.
  11. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Tammela T, Zarkada G, Wallgard E, Murtomäki A, Suchting S, Wirzenius M, Waltari M, Hellström M, Schomber T, Peltonen R, Freitas C, Duarte A, Isoniemi H, Laakkonen P, Christofori G, Ylä-Herttuala S, Shibuya M, Pytowski B, Eichmann A, Betsholtz C, Alitalo K. Nature 454: 656-60, 2008.
  12. Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation. Tammela T, Saaristo A, Holopainen T, Lyytikkä J, Kotronen A, Pitkonen M, Abo-Ramadan U, Ylä-Herttuala S, Petrova TV, Alitalo K. Nature Medicine 13: 1458-66, 2007.
  13. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, Harding T, Jooss K, Takahashi T, Alitalo K. Cancer Res 65: 4739-46, 2005.
  14. Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis. Petrova TV, Karpanen T, Norrmen C, Mellor R, Tamakoshi T, Finegold D, Ferrell R, Kerjaschki D, Mortimer P, Yla-Herttuala S, Miura N, Alitalo K. Nature Medicine 10: 974-81, 2004.
  15. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Karkkainen MJ, Haiko P, Sainio K, Partanen J, Taipale J, Petrova TV, Jeltsch M, Jackson DG, Talikka M, Rauvala H, Betsholtz C, Alitalo K. Nature Immunology 5:74-80, 2004.
  16. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, Alitalo K. J Natl Cancer Inst 94: 819-25, 2002.
  17. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Mäkinen T, Jussila L, Veikkola T, Kärpänen T, Kettunen MI, Pulkkanen KJ, Kauppinen R, Jackson DG, Kubo H, Nishikawa SI, Ylä-Herttuala S, Alitalo K. Nature Medicine 7: 199-205, 2001.
  18. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, Banerji S, Huarte J, Montesano R, Jackson DG, Orci L, Alitalo K, Christofori G, Pepper MS. EMBO J 20:672-82, 2001.
  19. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yla-Herttuala S, Jaattela M, Alitalo K. Cancer Res 61:1786-90, 2001.
  20. A model for gene therapy of human hereditary lymphedema. Karkkainen MJ, Saaristo A, Jussila L, Karila KA, Lawrence EC, Pajusola K, Bueler H, Eichmann A, Kauppinen R, Kettunen MI, Yla-Herttuala S, Finegold DN, Ferrell RE, Alitalo K. Proc Natl Acad Sci USA 98: 12677-82, 2001.
  21. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Karkkainen MJ, Ferrell RE, Lawrence EC, Kimak MA, Levinson KL, McTigue MA, Alitalo K, Finegold DN. Nature Genetics 25: 153-159, 2000.
  22. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Dumont DJ, Jussila L, Taipale J, Lymboussaki A, Mustonen T, Pajusola K, Breitman M, Alitalo K. Science 282: 946-949, 1998.
  23. Vascular endothelial growth factor-C induces angiogenesis in vivo. Cao Y, Linden P, Farnebo J, Cao R, Eriksson A, Kumar V, Qi JH, Claesson-Welsh L, Alitalo K. Proc Natl Acad Sci USA 95: 14389-14394, 1998.
  24. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, Swartz M, Fukumura D, Rakesh KJ, Alitalo K. Science 276: 1423-1425, 1997.
  25. Proteolytic processing regulates receptor specificity and activity of VEGF-C. Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, Cao Y, Saksela O, Kalkkinen N, Alitalo K. EMBO J 16: 3898-3911, 1997.